Omnio AB attracts EUR 1.5 million in capital investment – aims for first clinical trials in 2024
The drug could mean a global treatment revolution for wounds that never heal. Now, the Umeå-based biopharmaceutical company Omnio AB has received a capital injection of 1.5 million euros from its shareholders, which will be used for ongoing development work and to begin creating a blueprint for manufacturing.